In addition, it was evident that Trametinib inhibits BRAF V600 mutation-positive melanoma cell growth both in vitro and in vivo through activating MEK1/2 to regulate ERK pathway, which had been approved by Food and Drug Administration (FDA) to treat BRAF V600E or V600K mutation-positive melanoma and non–small cell lung cancer (Geraud et al., 2020; Roskoski, 2020). Here, BRAF is linked to melanoma.